Universal Broadband Infrastructure Fund: A Public-Private Model Using Shared Infrastructure and Outcome-Based Subsidies
Description
Establish a $50B Universal Broadband Infrastructure Fund (UBIF) — a global public fund capitalized by development banks and donor governments — that co-invests with private operators in last-mile infrastructure using a shared infrastructure and subsidy-for-outcomes model.
Core mechanisms: (1) Shared Infrastructure Mandate: All operators receiving UBIF capital must participate in a shared duct, fiber, and tower network model — eliminating duplicate buildout and reducing per-household cost by 40-60%. (2) Outcome-Based Subsidy: Government subsidies are tied to actual connectivity achieved, not capex deployed.
Operator receives baseline subsidy upon achieving 50% coverage; additional tranches at 70% and 90%. This aligns incentives with actual results rather than making investors whole regardless of adoption.
(3) Spectrum Efficiency Requirement: UBIF recipients must utilize TV White Space and shared spectrum in addition to licensed spectrum — expanding capacity without requiring new spectrum auctions.
(4) Cross-Border Regional Corridors: Fund pre-approves high-priority cross-border broadband corridors (US-Mexico, East Africa telecom belt, South Asia fiber corridors) to reduce regulatory uncertainty and enable regional economies of scale.
Implementation Pathway
Phase 1 (2025–2027)
- • UBIF capitalized at $50B by World Bank, regional development banks, G20 donors
- • Shared infrastructure standards finalized
- • First 50 cross-border regional corridors approved
Phase 2 (2027–2031)
- • 1B people connected through UBIF co-investment projects
- • Shared infrastructure operational in 30 countries
- • TV White Space spectrum enabled in 50 countries
Phase 3 (2031–2035)
- • 3B additional people connected
- • Universal broadband (>5 Mbps to 85% of population) achieved in all UBIF participating nations
Required Resources
Impact Analysis
Overall Net Impact
Combined analysis across all timeframes
Short-term
0-2 years
No benefits identified
No harms identified
Mid-term
3-10 years
No benefits identified
No harms identified
Long-term
10+ years
No benefits identified
No harms identified
